The key products and services being delivered under this indefinite delivery contract (IDC) awarded by the Defense Health Agency (DHA) are newborn screening testing services for the Brian Allgood Community Hospital (BAACH) and 121st Combat Support Hospital (CSH) in South Korea.
The prime contractor, Revvity Omics Inc. (doing business as Perkinelmer Genetics), a subsidiary of Revvity Inc., will perform this work at its own facilities in Pittsburgh, Pennsylvania. The contract has a total ceiling value of $375,013.10 and a period of performance from September 29, 2019 through September 28, 2024, with a base period and four one-year option periods. The contract was awarded as a single-award IDC with no set-aside designations. The contracted services entail conducting newborn screening tests to detect conditions like galactosemia, hypothyroidism, sickle cell disease, and cystic fibrosis, allowing for early diagnosis and treatment to support the military healthcare system and families stationed in Korea.
Generated 12/7/24, 9:04 AM